Fig. 4: MRI and pharmacokinetics of RMn-NBs in vitro and in vivo. | Nature Communications

Fig. 4: MRI and pharmacokinetics of RMn-NBs in vitro and in vivo.

From: Two-dimensional coordination risedronate-manganese nanobelts as adjuvant for cancer radiotherapy and immunotherapy

Fig. 4

a Measuring the longitudinal relaxation rates (r1) of RMn-NBs and commercial Fe3O4 contrast agent (n = 3 independent samples). b Measuring the transverse relaxation rates (r2) of RMn-NBs and commercial Fe3O4 contrast agent (n = 3 independent samples). c T2-weighted MRI of RMn-NBs and commercial Fe3O4 contrast agent (n = 3 independent samples). d Dynamic MRI after intravenous injection of RMn-NBs (10 mM × 0.2 mL) in CT26 tumor. The doses of Mn2+ and RANa are 5.5 mg kg−1 and 30.5 mg kg−1, respectively (n = 3 mice). e Relative MRI signal intensities of tumor and kidney regions in the 4T1 tumor-bearing mice at various time points (n = 3 mice). The dynamic concentrations of Mn2+ accumulated within (f) tumor and (g) kidney in the 4T1 tumor-bearing mice determined by inductively coupled plasma optical emission spectrometer (ICP-OES), respectively (n = 3 mice). h Pharmacokinetic profiles of free RANa and RMn-NBs in orthotopic 4T1 tumors. The dynamic concentrations of RANa accumulated within (i) tumor and (j) kidney of 4T1 tumor-bearing mice determined by HPLC, respectively (n = 3 mice). All data are shown as mean ± SD. Source data are provided as a Source Data file.

Back to article page